ACC.25: Bayer Presents New Investigational Heart Failure Data and Continued Portfolio Research in Chronic Kidney Disease in Type 2 Diabetes
Bayer announced today that data from 13 new analyses from across the KERENDIA® (finerenone) comprehensive clinical trial program will be presented at the American College of Cardiology (ACC) 74th ...
Litigation, Debt, And Decline - Yet Bayer Seems Like A Buy
Bayer's 2024 annual results showed a 2.2% sales decline, with only free cash flow improving significantly. Read why BAYZF ...